{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470609987
| IUPAC_name = ''N''-(2-chloro-4-methylthiophen-3-yl)-4,5-dihydro-1''H''-imidazol-2-amine
| image = Tiamenidine.svg
| width = 180

<!--Clinical data-->
| tradename = Sundralen, Symcorad, Symcor
| pregnancy_category =
| legal_status =
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
| elimination_half-life = 2.3–5 hours<ref>{{cite journal|last1=Eckert|first1=HG|last2=Baudner|first2=S|last3=Weimer|first3=KE|last4=Wissmann|first4=H|title=Determination of Tiamenidine in Biological Specimens by Radioimmunoassay|journal=Arzneimittel-Forschung|date=1981|volume=31|issue=3|pages=419–24|pmid=7194666}}</ref>
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 31428-61-2
| ATC_prefix = C02
| ATC_suffix = AC
| PubChem = 39974
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 36548
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 195V08O55G
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06127
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 295409
| synonyms =

<!--Chemical data-->
| C=8 | H=10 | Cl=1 | N=3 | S=1
| molecular_weight = 215.70 g/mol
| smiles = Clc2scc(c2N/C1=N/CCN1)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C8H10ClN3S/c1-5-4-13-7(9)6(5)12-8-10-2-3-11-8/h4H,2-3H2,1H3,(H2,10,11,12)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CVWILQHZFWRYPB-UHFFFAOYSA-N
}}

'''Tiamenidine''' ([[British Approved Name|BAN]], [[United States Adopted Name|USAN]], [[International Nonproprietary Name|INN]], also known as '''thiamenidine''', '''Hoe 440''') is a [[imidazoline]] compound that shares many of the pharmacological properties of [[clonidine]]. It acts as a centrally-acting [[Alpha-1 adrenergic receptor|α<sub>1</sub>]] and [[Alpha-2 adrenergic receptor|α<sub>2</sub> adrenergic receptor]] antagonist (with [[IC50]] 4.85 ''μ''M and 0.0091 ''μ''M, respectively).<ref>{{cite journal|last1=Timmermans|first1=PB|last2=de Jonge|first2=A|last3=Thoolen|first3=MJ|last4=Wilffert|first4=B|last5=Batink|first5=H|last6=van Zwieten|first6=PA|title=Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.|journal=Journal of Medicinal Chemistry|date=April 1984|volume=27|issue=4|pages=495–503|pmid=6142954|doi=10.1021/jm00370a011}}</ref> In hypertensive volunteers, like clonidine, it significantly increased sinus node recovery time and lowered [[cardiac output]].<ref>{{cite journal|last1=Roden|first1=DM|last2=Nadeau|first2=JH|last3=Primm|first3=RK|title=Electrophysiologic and Hemodynamic Effects of Chronic Oral Therapy With the Alpha 2-agonists Clonidine and Tiamenidine in Hypertensive Volunteers|journal=Clinical Pharmacology and Therapeutics|date=June 1988|volume=43|issue=6|pages=648–54|pmid=2897889|doi=10.1038/clpt.1988.90}}</ref> It was marketed (as tiamenidine hydrochloride) by [[Sanofi-Aventis]]<ref>{{cite web|title=Pharmaceutical and healthcare online databases. Tiamenidine Hydrochloride|url=http://drugs-about.com/drugs-s/sundralen.html|website=Drugs-About.com|accessdate=30 November 2015}}</ref> under the brand name '''Sundralen'''<ref>{{cite book|editor1-last=Ganten|editor1-first=D|editor2-last=Mulrow|editor2-first=Patrick J.|title=Pharmacology of Antihypertensive Therapeutics|date=2013|publisher=Springer-Verlag Berlin Heidelberg|location=[S.l.]|isbn=978-3-642-74211-8|page=880|edition=1st}}</ref> for the management of [[essential hypertension]].<ref name = "Zamboulis">{{cite journal|last1=Zamboulis|first1=C|last2=Hossmann|first2=V|last3=Dollery|first3=CT|last4=Eckert|first4=H|title=Tiamenidine, a Centrally Acting Antihypertensive Drug in Essential Hypertension [proceedings].|journal=British Journal of Clinical Pharmacology|date=October 1979|volume=8|issue=4|pages=390|pmid=508528}}</ref>

==Synthesis==
[[File:Tiamenidine-synthesis.svg|700px|center|thumb|Tiamenidine synthesis:<ref>Rippel, H.; Ruschig, H.; Linder, E.; Schorr, M.; 1973, {{US Patent|3,758,476}}</ref>]]
Reaction of thiourea '''1''' with [[methyl iodide]] gives the corresponding S-methyl analogue ('''2'''), followed by heating with [[ethylenediamine]], completes the synthesis of tiamenidine ('''3''').

==See also==
* [[Clonidine]]
* [[Tizanidine]]

==References==
{{reflist}}

{{Antihypertensives and diuretics}}
{{Adrenergics}}

[[Category:Abandoned drugs]]
[[Category:Alpha-adrenergic agonists]]
[[Category:Antihypertensive agents]]
[[Category:Chloroarenes]]
[[Category:Imidazolines]]
[[Category:Thiophenes]]